CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteHigh efficiency cell-specific targeting of cytokine activityA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroVeltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerTargeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitroInterferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.Advances in the treatment of hematologic malignancies using immunoconjugatesA new class of bispecific antibodies to redirect T cells for cancer immunotherapy.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Combination strategies to enhance antitumor ADCC.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.Bispecific antibodies: design, therapy, perspectives.A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.
P2860
Q28066935-71DA9AD0-A14F-4808-8C90-2C9A2B0B5949Q28305410-A4910551-CC14-484E-8E0C-1D3252C03E7EQ28728917-32F9E582-9652-49D4-B263-70A32D29B270Q33388543-1145094B-1B4D-4A11-96E4-3DC5F4F7E564Q33587482-1EF259F4-891A-40F6-BE13-E9E6ABD33E1AQ33788697-DEC29D06-0264-4E07-8967-B6C63AEF5BDDQ34096874-E6A5FCEB-7CED-4A38-A5A4-9AB800212AE6Q34645498-54A64A84-32C5-48FA-AF36-BC2C3AC59D0EQ34734013-374B733C-F18B-4D84-882B-04FF2F112792Q35163167-B4CE45E1-DBF3-4DED-97A3-E9ECEE077A14Q35172476-E6342DE3-D69E-43BC-A037-F45FB1F99087Q36127898-F9A944B4-B224-486B-A527-0F8037D6AD58Q36528137-97D3CBF1-5BD2-4E9D-A49C-DEF10797911AQ37697843-CECCB840-49BB-48BA-98A1-831038E210C4Q37698921-D670E928-33B3-4B39-ACA9-467ABD78DD99Q37720857-660DD9F2-0C5B-4225-96D7-E6DFF64931A2Q38014085-F9FF41C0-6E50-430C-9627-6851681B4614Q38014920-07BB7234-35A3-4C09-99CE-0511E55F6125Q38017203-CC0074C5-A6B4-4C18-9B12-3B33AB8FAB0FQ38025094-DAAD8143-F67F-4484-A1F5-63F217F9CA5AQ38402634-F0D7B6BB-7B12-4650-84B1-55948C3B565DQ38807514-A654EDC1-DA3C-4925-AA0B-BE2932855397Q39562454-B7056A4A-790B-4388-A76D-1B6F6B8E7218Q39609067-084E6D7C-ECE7-40FA-96D7-A3F159582155Q40976323-13B62B21-646D-40C5-9394-17340856DEB3Q49195146-20E29ED3-B1E6-4FBE-8735-3A00CCF0AFF7Q50538951-AC087D5B-CE03-4D23-9FF2-07291E15FA8E
P2860
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@ast
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@en
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@nl
type
label
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@ast
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@en
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@nl
prefLabel
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@ast
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@en
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@nl
P2093
P2860
P1433
P1476
CD20-targeted tetrameric inter ...... e therapy of B-cell lymphomas.
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Edmund A Rossi
Rhona Stein
Thomas M Cardillo
P2860
P304
P356
10.1182/BLOOD-2009-06-228890
P407
P577
2009-08-26T00:00:00Z